Proactive Investors
16 Jun 2026, 15:50 UTC · 1h ago
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
16 Jun 2026, 15:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Rhythm Pharmaceuticals reported that setmelanotide produced robust and sustained weight loss in patients with acquired hypothalamic obesity over a 2.5-year period. — Long-term durability data for a chronic condition treatment is a critical milestone for regulatory approval and commercial viability.
+0.60Rhythm Pharmaceuticals' bivamelagon therapy showed progressive reductions in BMI and hunger measures in acquired hypothalamic obesity patients at one year. — Positive early-stage data for a secondary asset expands the company's pipeline potential in the obesity space.
+0.40Blockmate Ventures' 110-acre Wyoming site features dual fiber connectivity and proximity to a substation, supporting its suitability for AI data center development. — Infrastructure readiness (power and connectivity) reduces execution risk for data center projects, though the scale is relatively small.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Reported robust, sustained, and clinically significant weight loss results for setmelanotide and positive data for bivamelagon.
Chairman stated that the company's site meets key requirements for AI data centre development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
10h ago
